Cannabinoid hyperemesis syndrome: An emerging drug-induced disease

American Journal of Therapeutics

Volumn 23, Issue 2, 2016, Pages e601-e605

  Woods, J Andrew ^a,b   Wright, Nicholas J D ^a   Gee, Jonathan ^b   Scobey, Martin W ^b  

^a WINGATE UNIVERSITY   (United States)

^b CAROLINAS MEDICAL CENTER   (United States)

Author keywords

cannabinoid hyperemesis; cyclic nausea; marijuana

Indexed keywords

ANTIEMETIC AGENT; CANNABINOID; CANNABIS; CHLORDIAZEPOXIDE PLUS CLIDINIUM BROMIDE; CREATININE; DOCUSATE SODIUM; OMEPRAZOLE; ONDANSETRON; PROMETHAZINE; SIMETHICONE; TRAMADOL; CANNABINOID 1 RECEPTOR; DRONABINOL;

ABDOMEN; ABDOMINAL PAIN; ADULT; AFRICAN AMERICAN; ALGORITHM; ANALGESIA; ARTICLE; CANNABINOID HYPEREMESIS SYNDROME; CANNABIS ADDICTION; CASE REPORT; CREATININE BLOOD LEVEL; DIET; DRUG INDUCED DISEASE; FEVER; HEAT; HEATING; HUMAN; HUMAN CELL; HYDRATION; HYPERPIGMENTATION; KIDNEY DYSFUNCTION; LABORATORY TEST; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MUCOSAL DRYNESS; NAUSEA; NAUSEA AND VOMITING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCAR FORMATION; SCORING SYSTEM; SCREENING; UREA NITROGEN BLOOD LEVEL; URINALYSIS; VITAL SIGN; VOMITING; CHEMICALLY INDUCED; COMPLICATION; FEMALE; PHYSIOLOGY; PREGNANCY; SYNDROME;

ABDOMINAL PAIN; ADULT; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NAUSEA; PREGNANCY; RECEPTOR, CANNABINOID, CB1; SYNDROME; VOMITING;

EID: 84891793116     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0000000000000034     Document Type: Article

References (30)

1. National Institute of Drug Abuse. Drugs of abuse and related topics: marijuana. Available at: www.nida. nih.gov/DrugPages/Marijuana.html. Accessed June 21, 2011
2. Compton WM, Grant BF, Colliver JD, et al. Prevalence of marijuana use disorders in the United States: 1991-1992 and 2001-2002. JAMA. 2004; 291: 2114-2121
3. Degenhardt L, Chiu WT, Sampson N, et al. Toward a global view of alcohol, tobacco, cannabis, and cocaine use: findings from the WHO World Mental Health Survey. PLoS Med. 2008; 5: e141
4. Adler JN, Colber JA. Clinical decisions. Medicinal use of marijuana-polling results. N Engl J Med. 2013; 368: e30
5. ProCon.org. Medical marijuana. June 2013. Available at: http://medicalmarijuana.procon.org/view.resource. php?resourceID5000881. Accessed June 21, 2013
6. Allen JH, de Moore GM, Heddle R, et al. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut. 2004; 53: 1566-1570
7. Wallace D, Martin AL, Park B. Cannabinoid hyperemesis: marijuana puts patients in hot water. Australas Psychiatry. 2007; 15: 156-158
8. Chepyala P, Olden KW. Cyclic vomiting and compulsive bathing with chronic cannabis abuse. Clin Gastroenterol Hepatol. 2008; 6: 710-712
9. Watts M. Cannabinoid hyperemesis presenting to a New Zealand hospital. N Z Med J. 2009; 122: 116-118
10. Chang YH, Windish DM. Cannabinoid hyperemesis relieved by compulsive bathing. Mayo Clin Proc. 2009; 84: 76-78
11. Sontineni SP, Chaudhary S, Sontinene V, et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an under-recognized manifestation of chronic cannabis abuse. World J Gasteroenterol. 2009; 15: 1264-1266
12. Patterson DA, Smith E, Monahan M, et al. Cannabinoid hyperemesis and compulsive bathing: a case series and paradoxical pathophysiological explanation. J Am Board Fam Med. 2010; 23: 790-793
13. Soriano-Co M, Batke M, Cappell MS. The cannabis hyperemesis syndrome characterized by persistent nausea and vomiting, abdominal pain, and compulsive bathing associated with chronic marijuana use: a report of eight cases in the United States. Dig Dis Sci. 2010; 55: 3113-3119
14. Donnino MW, Cocchi MN, Miller J, et al. Cannabinoid hyperemesis: a case series. J Emerg Med. 2011; 40: e63-e66
15. Nicolson SE, Denysenko L, Mulcare JL, et al. Cannabinoid hyperemesis syndrome: a case series and review of previous reports. Psychosomatics. 2012; 53: 212-219
16. Simonetto DA, Oxentenko AS, Herman ML, et al. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012; 87: 114-119
17. Abell TL, Adams KA, Boles RG, et al. Cyclic vomiting syndrome in adults. Neurogastroenterol Motil. 2008; 20: 269-284
18. Darmani NA, Ray AP. A re-evaluation of the neurochemical and anatomical bases of chemotherapyinduced vomiting. Chem Rev. 2009; 109: 3158-3199
19. Panikashvili D, Mechoulam R, Beni SM, et al. CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab. 2005; 25: 477-488
20. Watson SJ, Benson JA, Joy JE. Marijuana and medicine: assessing the science base: a summary of the 1999 Institute of Medicine report. Arch Gen Psychiatry. 2000; 57: 547-552
21. Kwiatkowska M, Parker LA, Burton P, et al. A comparative analysis of the potential of cannabinoids and ondansetron to suppress cisplatin-induced emesis in the Suncus murinus (house musk shrew). Psychopharmacology (Berl). 2004; 174: 254-259
22. Del Mar Ramirez Fernandez M, De Boeck G, Wood M, et al. Simultaneous analysis of THC and its metabolites in blood using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008; 875: 465-470
23. Darmani NA. Cannabinoid-induced hyperemesis: a conundrum-from clinical recognition to basic science mechanisms. Pharmaceuticals. 2010; 3: 2163-2177
24. Simoneau II, Hamza MS, Mata HP, et al. The cannabinoid agonist WIN55, 212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology. 2001; 94: 882-887
25. Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther. 2010; 126: 21-38
26. Partosoedarso ER, Abrahams TP, Scullion R, et al. Cannabinoid 1 receptor in the dorsal vagal complex modulates lower esophageal sphincter relaxation in ferrets. J Physiol. 2003; 550: 149-158
27. Schulze DR, Carroll FI, McMahon LR. Interactions between dopamine transporter and cannabinoid receptor ligands in rhesus monkeys. Psychopharmacology (Berl). 2012; 222: 425-438
28. Desai RI, Thakur GA, Vemuri VK, et al. Analysis of tolerance and behavioral/physical dependence during chronic CB1 agonist treatment: effects of CB1 agonist, antagonist and noncannabinoid drugs. J Pharmacol Exp Ther. 2013; 344: 319-328
29. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013; 31: 1003. e5-6
30. Crowley TJ, MacDonald MJ, Whitmore EA, et al. Cannabis dependence, withdrawal and reinforcing effects amongst adolescents with conduct symptoms and substance abuse disorders. Drug Alchol Depend. 1998; 50: 27-37